Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Jan 21

PMID 36672617

Authors

Krisida Cerma

Federico Piacentini

Luca Moscetti

Monica Barbolini

Fabio Canino

Antonio Tornincasa

Federica Caggia

Sara Cerri

Alessia Molinaro

Massimo Dominici

Claudia Omarini

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in several cases. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway mutations are frequent in BC (20-40%) and are significant causes of aggressive tumor behavior, as well as treatment resistance. Improving knowledge of the PI3K/AKT/mTOR pathway is an urgent need. This review aims to highlight the central role of PI3K-mTORC1/C2 mutations in the different BC subtypes, in terms of clinical outcomes and treatment efficacy. The broad base of knowledge in tumor biology is a key point for personalized BC therapy in the precision medicine era.

Citing Articles

Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?.

Berkley K, Zalejski J, Sharma A Cancers (Basel). 2025; 17(5).

PMID: 40075607 PMC: 11898704. DOI: 10.3390/cancers17050755.

Metabolic Switch in Endocrine Resistant Estrogen Receptor Positive Breast Cancer.

Brechbuhl H, Han A, Paul K, Nemkov T, Ramachandran S, Ward A bioRxiv. 2025; .

PMID: 39763830 PMC: 11703175. DOI: 10.1101/2024.12.28.630631.

Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.

Guo X, Zuo Z, Wang X, Sun Y, Xu D, Liu G Cardiooncology. 2024; 10(1):92.

PMID: 39716319 PMC: 11665102. DOI: 10.1186/s40959-024-00298-y.

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs.

Smilkou S, Kaklamanis L, Balgouranidou I, Linardou H, Papatheodoridi A, Zagouri F Front Oncol. 2024; 14:1435559.

PMID: 39711963 PMC: 11659196. DOI: 10.3389/fonc.2024.1435559.

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative....

Fanucci K, Giordano A, Erick T, Tolaney S, Sammons S ESMO Open. 2024; 9(12):103997.

PMID: 39674130 PMC: 11699375. DOI: 10.1016/j.esmoop.2024.103997.

References

Mukhopadhyay S, Saqcena M, Foster D . Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience. 2015; 2(10):807-8. PMC: 4671930. DOI: 10.18632/oncoscience.253. View

Hagemann I . Molecular Testing in Breast Cancer: A Guide to Current Practices. Arch Pathol Lab Med. 2016; 140(8):815-24. DOI: 10.5858/arpa.2016-0051-RA. View

Chae Y, Davis A, Jain S, Santa-Maria C, Flaum L, Beaubier N . Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Mol Cancer Ther. 2017; 16(7):1412-1420. DOI: 10.1158/1535-7163.MCT-17-0061. View

Piccart M, Hortobagyi G, Campone M, Pritchard K, Lebrun F, Ito Y . Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014; 25(12):2357-2362. PMC: 6267855. DOI: 10.1093/annonc/mdu456. View

Martin M, Chan A, Dirix L, OShaughnessy J, Hegg R, Manikhas A . A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol. 2016; 28(2):313-320. DOI: 10.1093/annonc/mdw562. View

Goodwin P, Chen B, Gelmon K, Whelan T, Ennis M, Lemieux J . Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. 2022; 327(20):1963-1973. PMC: 9131745. DOI: 10.1001/jama.2022.6147. View

Frias M, Mukhopadhyay S, Lehman E, Walasek A, Utter M, Menon D . Phosphatidic acid drives mTORC1 lysosomal translocation in the absence of amino acids. J Biol Chem. 2019; 295(1):263-274. PMC: 6952608. DOI: 10.1074/jbc.RA119.010892. View

Buckner J, Forouzesh B, Erlichman C, Hidalgo M, Boni J, Dukart G . Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs. 2009; 28(3):334-42. DOI: 10.1007/s10637-009-9257-1. View

Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L . Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2.... Lancet Oncol. 2019; 20(9):1226-1238. DOI: 10.1016/S1470-2045(19)30334-1. View

10.

Asghar U, Barr A, Cutts R, Beaney M, Babina I, Sampath D . Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017; 23(18):5561-5572. PMC: 6175044. DOI: 10.1158/1078-0432.CCR-17-0369. View

11.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

12.

Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J . FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019; 30(8):1289-1297. DOI: 10.1093/annonc/mdz177. View

13.

Andre F, Hurvitz S, Fasolo A, Tseng L, Jerusalem G, Wilks S . Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016; 34(18):2115-24. DOI: 10.1200/JCO.2015.63.9161. View

14.

Zumsteg Z, Morse N, Krigsfeld G, Gupta G, Higginson D, Lee N . Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res. 2015; 22(8):2009-19. PMC: 4870591. DOI: 10.1158/1078-0432.CCR-15-2245. View

15.

Davies B, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J . Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012; 11(4):873-87. DOI: 10.1158/1535-7163.MCT-11-0824-T. View

16.

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

17.

Desmedt C, Voet T, Sotiriou C, Campbell P . Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol. 2012; 24(6):597-604. PMC: 3713550. DOI: 10.1097/CCO.0b013e328359554e. View

18.

Wolff A, Lazar A, Bondarenko I, Garin A, Brincat S, Chow L . Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2012; 31(2):195-202. PMC: 3532391. DOI: 10.1200/JCO.2011.38.3331. View

19.

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

20.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View